MM120 shows promise for treating anxiety with a minimum effective dose

A multi-arm clinical trial indicates that 100 micrograms of MM120 may provide up to 12 weeks of relief from generalized anxiety disorder (GAD). The study, conducted at UCSF's Neuroscape, suggests a dose-dependent response, with higher doses yielding better outcomes.

AI-generated summary — may contain errors. How it works